Intravenous Fat Emulsions Reduction for Patients with Parenteral Nutrition-Associated Liver Disease

被引:108
作者
Cober, Mary Petrea [1 ,3 ]
Killu, Ghassan [3 ]
Brattain, Allison [3 ]
Welch, Kathleen B. [4 ]
Kunisaki, Shaun M. [2 ]
Teitelbaum, Daniel H. [2 ]
机构
[1] Univ Michigan Hosp & Hlth Ctr, Dept Pharm, Ann Arbor, MI USA
[2] Univ Michigan Hosp & Hlth Ctr, Dept Surg, Ann Arbor, MI USA
[3] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA
关键词
SHORT-BOWEL SYNDROME; FISH-OIL; ACID DEFICIENCY; CHOLESTASIS; PREVENTION; MANAGEMENT; MORTALITY; INFUSION; INFANTS;
D O I
10.1016/j.jpeds.2011.08.047
中图分类号
R72 [儿科学];
学科分类号
100202 [儿科学];
摘要
Objective To test the hypothesis that implementation of a marked reduction in intravenous fat will result in reversal of parenteral nutrition-associated liver disease (PNALD) in infants. Study design Prospective study of intravenous fat emulsion reduction in parenteral nutrition to 1 g/kg/d 2 times per week in neonates diagnosed with PNALD. Primary outcome measure was total bilirubin levels compared with gestational age, birth weight, and diagnosis-matched historical controls receiving 3 g/kg/d of intravenous lipids. Results Intravenous fat emulsion reduction resulted in a significant decline in total bilirubin levels compared with controls. Comparison of growth in the 2 groups was similar. Mild essential fatty acid deficiency was detected in 8 of 31 infants and was reversed with additional days of lipid infusion. No significant adverse events were noted. Conclusions An association between intravenous lipid emulsion administration and the development of PNALD seems probable. Use of intravenous fat emulsion reduction is a potential approach to reverse PNALD in young infants. Frequent monitoring of essential fatty acid deficiency is needed with the use of this regimen. (J Pediatr 2012; 160:421-7).
引用
收藏
页码:421 / 427
页数:7
相关论文
共 30 条
[1]
ALLARDYCE DB, 1982, SURG GYNECOL OBSTET, V154, P641
[2]
Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes [J].
Andorsky, DJ ;
Lund, DP ;
Lillebei, CW ;
Jaksic, T ;
DiCanzio, J ;
Richardson, DS ;
Collier, SB ;
Lo, C ;
Duggan, C .
JOURNAL OF PEDIATRICS, 2001, 139 (01) :27-33
[3]
[Anonymous], 2002, JPEN J PARENTER ENTE
[4]
[Anonymous], 2006, LINEAR MIXED MODELS
[5]
BEALE EF, 1979, PEDIATRICS, V64, P342
[6]
Analysis of patients with longitudinal intestinal lengthening procedure referred for intestinal transplantation [J].
Bueno, J ;
Guiterrez, J ;
Mazariegos, GV ;
Abu-Elmagd, K ;
Madariaga, J ;
Ohwada, S ;
Kocoshis, S ;
Reyes, J .
JOURNAL OF PEDIATRIC SURGERY, 2001, 36 (01) :178-183
[7]
Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR [J].
Carter, Beth A. ;
Taylor, Olga A. ;
Prendergast, Daniel R. ;
Zimmerman, Tracy L. ;
Von Furstenberg, Richard ;
Moore, David D. ;
Karpen, Saul J. .
PEDIATRIC RESEARCH, 2007, 62 (03) :301-306
[8]
Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure [J].
Cavicchi, M ;
Beau, P ;
Crenn, P ;
Degott, C ;
Messing, B .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (07) :525-532
[9]
PHYTOSTEROLEMIA IN CHILDREN WITH PARENTERAL-NUTRITION ASSOCIATED CHOLESTATIC LIVER-DISEASE [J].
CLAYTON, PT ;
BOWRON, A ;
MILLS, KA ;
MASSOUD, A ;
CASTEELS, M ;
MILLA, PJ .
GASTROENTEROLOGY, 1993, 105 (06) :1806-1813
[10]
The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition [J].
Clayton, PT ;
Whitfield, P ;
Iyer, K .
NUTRITION, 1998, 14 (01) :158-164